Indoleamine 2,3 Dioxygenase 1 Market
Global Indoleamine 2,3 Dioxygenase 1 Market Size, Share, and Trends Analysis Report by Type (BMS-986205, Dcellvax, Epacadostat, F-001287, Galanal, and Others), and by Application (Alopecia, Cervical Cancer, Gastric Cancer, Glioma, and Others) Forecast Period (2022-2028)
The global indoleamine 2,3 dioxygenase 1 market is anticipated to grow at a substantial CAGR during the forecast period. Indoleamine 2,3 dioxygenase 1 (IDO) is an enzyme that catalyzes the degradation of the essential amino acid tryptophan in many types of cells including dendritic cells (DCs), which has been proposed to be an authentic regulator of immune responses. The heme enzyme in indoleamine 2,3 dioxygenase 1 (IDO1) catalyzes the oxidation of L-tryptophan, which is the first step of the kynurenine pathway. IDO1 is widely being used for cancer immune escape and overexpression of IDO1 has been linked to poor prognosis in many malignancies. Thus, the increased prevalence of cancer across the globe is one of the key factors which is bolstering the growth of the market.
Impact of COVID-19 on Global Indoleamine 2,3 Dioxygenase 1 Market
COVID-19 has had a major influence on the global indoleamine 2,3 dioxygenase 1 market. Healthcare professionals working at the US-based Dana Farber Cancer Institute published a paper in Cancer Connect in 2020, which concluded that during COVID-19, there was a 46% decline in diagnoses of the six most frequent cancer types that including breast, colorectal, lung, pancreatic, gastric, and esophageal cancers. In addition, the Centers for Disease Control and Prevention (CDC) and many medical professional organizations advised that cancer screening and other health-prevention services, as well as elective surgeries, be postponed unless the risks outweighed the benefits and that hospitals be prepared to treat COVID-19 patients. As a result of COVID-19, the overall cancer therapeutics market had been damaged, further hindering the growth of the indoleamine 2,3 dioxygenase 1 market.
Segmental Outlook
The global indoleamine 2,3 dioxygenase 1 market is segmented based on type and application. Based on type, the market is segmented into BMS-986205, dcellvax, epacadostat, F-001287, galanal, and others. Based on application the market is segmented into alopecia, cervical cancer, gastric cancer, glioma, and others. The above-mentioned segments can be customized as per the requirements.
Global Indoleamine 2,3 Dioxygenase 1 Market Share by Type, 2021(%)
BMS-986205 Segment is Holding a Prominent Share in the Global Indoleamine 2,3 Dioxygenase 1 Market
Based on the type, the BMS-986205 sub-segment is expected to grow at a considerable CAGR over the forecast period among the indoleamine 2,3 dioxygenase 1 market. The growth is attributed owing to the increasing clinical trials in combination with various types of drug inhibitors across the globe. For instance, in 2019, the U.S. National Library of Medicine conducted a study of BMS-986205 alone and in combination with Nivolumab in Chinese patients suffering from advanced Malignant solid tumors.
Regional Outlooks
The global indoleamine 2,3 dioxygenase 1 market is further segmented based on geography Including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement.
Global Indoleamine 2,3 Dioxygenase 1 Market Growth, by Region 2022-2028
North America is Expected to Hold a Prominent Market Share in the Global Indoleamine 2,3 Dioxygenase 1 Market
Among all the regions, the North American region is expected to hold a prominent market size in the indoleamine 2,3 dioxygenase 1 market during the forecast period. The major factor c=supporting in the regional growth is the rapidly rising incidences of various types of cancer across the countries such as the US and Canada. According to the American Cancer Society, in 2018, it was anticipated that 1.9 million new cancer cases and 693,000 cancer deaths occurred in Northern America. Prostate cancer in men and breast cancer in women is the most commonly diagnosed cancers, whereas lung cancer is the most prevalent cause of cancer mortality in both sexes.
Market Players Outlook
The major companies serving the global Indoleamine 2,3 Dioxygenase 1 market include Bristol-Myers Squibb, Merck KGaA, BirchBioMed Inc., Genentech Inc., F. Hoffmann-La Roche Ltd., and others. To enhance their market share, industry participants are employing several critical techniques. For instance, The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended that nivolumab (Opdivo) and ipilimumab (Yervoy) be approved for use in the frontline treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) with a PD-L1 expression of 1% or higher.1
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global indoleamine 2,3 dioxygenase 1 market. Based on the availability of data, information related to new product launches, and relevant news is additionally available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Indoleamine 2,3 Dioxygenase 1 Market
• Recovery Scenario of Global Indoleamine 2,3 Dioxygenase 1 Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Bristol-Myers Squibb
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Merck KGaA
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. BirchBioMed Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. Swot Analysis
3.3.4. Recent Developments
3.4. Genentech Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. F. Hoffmann-La Roche Ltd.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Indoleamine 2,3 Dioxygenase 1 Market by Type
4.1.1. BMS-986205
4.1.2. Dcellvax
4.1.3. Epacadostat
4.1.4. F-001287
4.1.5. Galanal
4.1.6. Others
4.2. Global Indoleamine 2,3 Dioxygenase 1 Market by Application
4.2.1. Alopecia
4.2.2. Cervical Cancer
4.2.3. Gastric Cancer
4.2.4. Glioma
4.2.5. Others
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Globavir Biosciences Inc.
6.2. Incyte Corp.
6.3. IO Biotech
6.4. Kyowa Kirin Co., Ltd.
6.5. Netherlands Translational Research Center B.V. (NTRC)
6.6. NewLink Genetics Corporation (NewLink Genetics)
6.7. Pfizer, Inc.
6.8. Redx Pharma Plc
6.9. Regen biopharma Inc.
1. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL BMS-986205 INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL DCELLVAX INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL EPACADOSTAT INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL F-001287 INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL GALANAL INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL OTHERS INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028($ MILLION)
9. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 FOR ALOPECIA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
10. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 FOR CERVICAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
11. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 FOR GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
12. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 FOR GLIOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
13. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
14. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028($ MILLION)
15. NORTH AMERICAN INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. NORTH AMERICAN INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
17. NORTH AMERICAN INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
18. EUROPEAN INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. EUROPEAN INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028($ MILLION)
20. EUROPEAN INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
21. ASIA-PACIFIC INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. ASIA-PACIFIC INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
23. ASIA-PACIFIC INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
24. REST OF THE WORLD INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
25. REST OF THE WORLD INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
26. REST OF THE WORLD INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET, 2022-2028 (%)
4. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL BMS-986205 INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL DCELLVAX INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL EPACADOSTAT INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL F-001287 INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL GALANAL INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL OTHERS INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
12. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 FOR ALOPECIA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 FOR CERVICAL CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 FOR GASTRIC CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 FOR GLIOMA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 FOR OTHER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
17. GLOBAL INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
18. US INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
19. CANADA INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
20. UK INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
21. FRANCE INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
22. GERMANY INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
23. ITALY INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
24. SPAIN INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
25. REST OF EUROPE INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
26. INDIA INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
27. CHINA INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
28. JAPAN INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
29. SOUTH KOREA INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
30. REST OF ASIA-PACIFIC INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
31. REST OF THE WORLD INDOLEAMINE 2,3 DIOXYGENASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
